Novo Nordisk pushed out a press release this week in the spirit of “My Dog’s Better Than Your Dog.” The gist of it was to claim that Novo’s Wegovy (semaglutide) tablets are best in comparison to the newly approved Foundayo (orforglipron) tablets for obesity treatment. The basis for the claim? A “simulated treatment comparison” soon […]
